Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.

White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p < 0.01), with larger effects observed in patients selected using the company’s biomarker enrichment strategy.

BOCA RATON, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced new imaging data from its Phase 2 study of XPro in patients with early Alzheimer’s disease (AD). The data, to be presented at the Alzheimer’s Association International Conference (AAIC), support early, concordant treatment-related effects across independent white matter and gray matter imaging endpoints.

The presentation, titled "Concordant White Matter and Cortical Treatment Effects in a Phase 2 Study of XPro1595 in Early Alzheimer’s disease," highlights the full chi-separation analysis of white matter myelin, together with cortical disarray measurement (CDM), an advanced diffusion-MRI measure of gray matter microstructure. The two techniques rely on different MRI contrast mechanisms: chi-separation uses magnetic susceptibility, while CDM uses water diffusion. They also use separate acquisition sequences and processing pipelines and, in this study, were applied to different tissue compartments. Because these methodologically independent measures changed in the same direction, their concordance supports the interpretation that the observed changes are treatment-related and reflect effects on brain microstructure.